Xponance Inc. boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 1.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 26,762 shares of the life sciences company’s stock after buying an additional 264 shares during the period. Xponance Inc.’s holdings in Illumina were worth $2,123,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Rakuten Securities Inc. boosted its stake in Illumina by 290.3% during the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company’s stock worth $29,000 after buying an additional 270 shares during the last quarter. Center for Financial Planning Inc. acquired a new position in shares of Illumina in the 1st quarter valued at $33,000. Fourth Dimension Wealth LLC acquired a new position in shares of Illumina in the 4th quarter valued at $40,000. PFS Partners LLC lifted its stake in shares of Illumina by 400.0% in the 1st quarter. PFS Partners LLC now owns 500 shares of the life sciences company’s stock valued at $40,000 after purchasing an additional 400 shares during the last quarter. Finally, Golden State Wealth Management LLC lifted its stake in shares of Illumina by 123.2% in the 1st quarter. Golden State Wealth Management LLC now owns 529 shares of the life sciences company’s stock valued at $42,000 after purchasing an additional 292 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.
Insider Activity
In other news, CFO Ankur Dhingra bought 6,100 shares of the firm’s stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average cost of $81.21 per share, with a total value of $495,381.00. Following the transaction, the chief financial officer directly owned 24,906 shares in the company, valued at $2,022,616.26. This trade represents a 32.44% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.17% of the stock is currently owned by company insiders.
Illumina Trading Down 0.7%
Illumina (NASDAQ:ILMN – Get Free Report) last announced its earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.96 by $0.01. The firm had revenue of $1.04 billion during the quarter, compared to analysts’ expectations of $1.03 billion. Illumina had a positive return on equity of 25.54% and a negative net margin of 22.25%. The business’s revenue was down 1.4% on a year-over-year basis. During the same period in the prior year, the firm earned $0.98 EPS. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
ILMN has been the topic of several recent analyst reports. JPMorgan Chase & Co. decreased their price target on Illumina from $120.00 to $85.00 and set a “neutral” rating on the stock in a research note on Friday, May 9th. Evercore ISI boosted their price objective on Illumina from $116.00 to $128.00 and gave the company an “outperform” rating in a report on Tuesday, July 8th. Morgan Stanley cut their price objective on Illumina from $136.00 to $100.00 and set an “equal weight” rating on the stock in a report on Monday, May 12th. Royal Bank Of Canada cut their price target on Illumina from $128.00 to $112.00 and set an “outperform” rating on the stock in a report on Tuesday, April 8th. Finally, Guggenheim cut their price target on Illumina from $122.00 to $114.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Illumina currently has a consensus rating of “Hold” and an average target price of $125.11.
Get Our Latest Stock Analysis on ILMN
Illumina Company Profile
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Further Reading
- Five stocks we like better than Illumina
- What is the Hang Seng index?
- These 3 Undervalued Stocks Could Surge as Value Rotation Nears
- How to Invest in Blue Chip Stocks
- Tilray Shares Blazing: What’s Behind the 55% Rally This Month?
- Investing in the High PE Growth Stocks
- 3 Retail Stocks to Watch as Back-to-School Spending Ramps Up
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.